CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

NEWARK, Calif., Nov. 28, 2016 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and orphan diseases, today announced that management will participate in a fireside chat at the 28^th Annual Piper Jaffray Healthcare Conference on November 30, 2016.

The audio portion of the fireside chat will be accessible live through the Investors page on the company’s website at http://ir.cymabay.com/events. A replay of the webcast will be available on the company’s website for 14 days following the event.

28^th Annual Piper Jaffray Healthcare Conference
Date:                                                     Wednesday, November 30
Time:                                                     3:00pm – 3:25pm Eastern Time
Place:                                                    The Lotte New York Palace Hotel
Webcast:                                             http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of MBX-8025 in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications.  Previously, a Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile.  Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.

For additional information about CymaBay visit www.cymabay.com. 

Contact: 
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800 
[email protected]

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]